Vor Biopharma Inc.
VOR
$2.17
-$0.03-1.36%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -66.76% | -17.67% | -17.49% | -13.15% | -12.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 738.82% | 2.99% | 11.33% | -19.26% | -9.76% |
| Operating Income | -738.82% | -2.99% | -11.33% | 19.26% | 9.76% |
| Income Before Tax | -5,552.75% | -5.46% | -16.95% | 16.97% | 7.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5,552.75% | -5.46% | -16.95% | 16.97% | 7.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5,552.75% | -5.46% | -16.95% | 16.97% | 7.14% |
| EBIT | -738.82% | -2.99% | -11.33% | 19.26% | 9.76% |
| EBITDA | -757.46% | -3.45% | -11.80% | 19.64% | 10.02% |
| EPS Basic | -2,981.97% | 42.51% | -13.30% | 18.01% | 8.86% |
| Normalized Basic EPS | -2,921.19% | 42.51% | -13.31% | 17.99% | 8.84% |
| EPS Diluted | -2,981.97% | 42.51% | -13.30% | 18.01% | 8.86% |
| Normalized Diluted EPS | -2,921.19% | 42.51% | -13.31% | 17.99% | 8.84% |
| Average Basic Shares Outstanding | 83.42% | 83.48% | 3.22% | 1.27% | 1.89% |
| Average Diluted Shares Outstanding | 83.42% | 83.48% | 3.22% | 1.27% | 1.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |